ZA201708006B - 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists - Google Patents
3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonistsInfo
- Publication number
- ZA201708006B ZA201708006B ZA2017/08006A ZA201708006A ZA201708006B ZA 201708006 B ZA201708006 B ZA 201708006B ZA 2017/08006 A ZA2017/08006 A ZA 2017/08006A ZA 201708006 A ZA201708006 A ZA 201708006A ZA 201708006 B ZA201708006 B ZA 201708006B
- Authority
- ZA
- South Africa
- Prior art keywords
- difluoropiperidine
- receptor antagonists
- heterocyclic compounds
- nmda receptor
- nr2b nmda
- Prior art date
Links
- -1 3,3-difluoropiperidine carbamate heterocyclic compounds Chemical class 0.000 title 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
- 108010054200 NR2B NMDA receptor Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562169107P | 2015-06-01 | 2015-06-01 | |
| PCT/US2016/035098 WO2016196513A1 (en) | 2015-06-01 | 2016-05-31 | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201708006B true ZA201708006B (en) | 2021-07-28 |
Family
ID=57441824
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2017/08006A ZA201708006B (en) | 2015-06-01 | 2017-11-24 | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US10584127B2 (enExample) |
| EP (1) | EP3303323B1 (enExample) |
| JP (1) | JP6876625B2 (enExample) |
| KR (1) | KR102613179B1 (enExample) |
| CN (1) | CN107849010B (enExample) |
| AR (1) | AR104837A1 (enExample) |
| AU (1) | AU2016270677B2 (enExample) |
| BR (1) | BR112017025023B1 (enExample) |
| CA (1) | CA2987606C (enExample) |
| DK (1) | DK3303323T3 (enExample) |
| ES (1) | ES2784398T3 (enExample) |
| IL (1) | IL255937B (enExample) |
| MX (1) | MX380424B (enExample) |
| RU (1) | RU2735277C2 (enExample) |
| TW (1) | TWI721987B (enExample) |
| WO (1) | WO2016196513A1 (enExample) |
| ZA (1) | ZA201708006B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015317886A1 (en) | 2014-09-15 | 2017-03-09 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists |
| EP3253761A4 (en) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| EP3303323B1 (en) | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| CN106986874B (zh) * | 2016-01-20 | 2019-09-24 | 西华大学 | (1H-吡唑[3,4-d]嘧啶)-4-氨基衍生物及其作为IDO抑制剂在药物制备中的用途 |
| EP3544610A1 (en) | 2016-11-22 | 2019-10-02 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4136103A4 (en) | 2020-04-17 | 2024-05-15 | HB Biotech, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES |
| CN117159541A (zh) * | 2023-09-20 | 2023-12-05 | 南华大学 | Nat10拮抗剂在制备预防和/或治疗癫痫的药物中的应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3717867A1 (de) | 1987-05-26 | 1988-12-15 | Schiepe Stapelautomaten Gmbh | Stapelvorrichtung |
| RU2140910C1 (ru) | 1995-08-11 | 1999-11-10 | Пфайзер Инк. | Тригидрат метансульфоната (1s,2s)-1-(4-гидроксифенил)-2-(4-гидрокси-4- фенилпиперидин-1-ил)-1-пропанола |
| GB9805977D0 (en) * | 1998-03-19 | 1998-05-20 | Silver Joshua D | Improvements in variable focus optical devices |
| US6476041B1 (en) | 1999-10-29 | 2002-11-05 | Merck & Co., Inc. | 1,4 substituted piperidinyl NMDA/NR2B antagonists |
| HU227197B1 (en) | 2000-10-24 | 2010-10-28 | Richter Gedeon Nyrt | Nmda receptor antagonist carboxylic acid amide derivatives and pharmaceutical compositions containing them |
| BR0207526A (pt) | 2001-02-23 | 2004-03-09 | Merck & Co Inc | Composto, composição farmacêutica, e, métodos para o tratamento da dor, da enxaqueca, depressão, ansiedade, esquizofrenia, doença de parkinson ou derrame cerebral |
| US7592360B2 (en) | 2003-06-04 | 2009-09-22 | Merck & Co., Inc. | 3-fluoro-piperidines as NMDA/NR2B antagonists |
| CN1798744A (zh) * | 2003-06-04 | 2006-07-05 | 麦克公司 | 作为nmda/nr2b拮抗剂的3－氟－哌啶化合物 |
| WO2005102390A2 (en) | 2004-04-22 | 2005-11-03 | Pfizer Japan, Inc. | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists |
| EP1797094A4 (en) | 2004-08-03 | 2009-06-03 | Merck & Co Inc | NMDA / NR2B ANTAGONISTS BASED ON 1,3 DISUBSTITUTED HETEROARYLATES |
| US20080086006A1 (en) * | 2004-12-22 | 2008-04-10 | Nelson Todd D | Process for Making Substituted Piperidines |
| CA2603876A1 (en) | 2005-04-19 | 2006-10-26 | Merck & Co., Inc. | N-alkyl-azacycloalkyl nmda/nr2b antagonists |
| WO2007061868A2 (en) | 2005-11-17 | 2007-05-31 | Trustees Of Tufts College | Treatment of stereotypic, self-injurious and compulsive behaviors using specific serotonin reuptake inhibitors and antagonists of nmda receptors |
| US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
| CA2662702A1 (en) | 2006-09-07 | 2008-03-13 | Merck & Co., Inc. | Difluorinated piperidines for treatment of alzheimer's disease and related conditions |
| BRPI0720986A2 (pt) * | 2006-12-27 | 2014-03-11 | Sanofi Aventis | Derivados de isoquinolina e isoquinolinona substituídos |
| KR20100135847A (ko) * | 2008-03-27 | 2010-12-27 | 에보텍 뉴로사이언시즈 게엠베하 | Ｎｍｄａ ｎｒ２ｂ―서브타입 선택적 길항제를 사용한 질병 치료 방법 |
| US20100010565A1 (en) * | 2008-07-09 | 2010-01-14 | Samuel Victor Lichtenstein | Extended range wireless muscular and neural stimulation |
| WO2010015637A1 (en) | 2008-08-06 | 2010-02-11 | Novartis Ag | New antiviral modified nucleosides |
| WO2011090666A2 (en) | 2009-12-28 | 2011-07-28 | Afraxis, Inc. | Methods for treating autism |
| DK2558446T5 (da) * | 2010-04-16 | 2019-12-09 | Ac Immune Sa | Nye forbindelser til behandling af sygdomme associerede med amyloid- eller amyloidlignende proteiner |
| US20130231348A1 (en) | 2010-06-09 | 2013-09-05 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
| US20130225575A1 (en) | 2010-06-16 | 2013-08-29 | Afraxis, Inc. | Methods for treating neurological conditions |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| WO2012123312A1 (en) * | 2011-03-11 | 2012-09-20 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| US9278910B2 (en) * | 2011-05-31 | 2016-03-08 | Receptos, Inc. | GLP-1 receptor stabilizers and modulators |
| US9387212B2 (en) * | 2012-04-20 | 2016-07-12 | Ucb Biopharma Sprl | Methods for treating Parkinson's disease |
| US9643957B2 (en) * | 2012-12-11 | 2017-05-09 | Takeda Pharmaceutical Company Limited | Heterocyclic compounds having cholesterol 24-hydroxylase activity |
| ES2618421T3 (es) | 2013-01-29 | 2017-06-21 | Aptinyx Inc. | Moduladores espiro-lactama del receptor NMDA y usos de los mismos |
| JP2017500287A (ja) * | 2013-11-06 | 2017-01-05 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体 |
| US9221796B2 (en) * | 2014-01-09 | 2015-12-29 | Bristol-Myers Squibb Company | Selective NR2B antagonists |
| MX2016014581A (es) | 2014-05-06 | 2018-02-16 | Univ Northwestern | Composiciones de compuestos que modulan nmdar. |
| JP2017516836A (ja) | 2014-06-04 | 2017-06-22 | リューゲン ホールディングス （ケイマン） リミテッド | Ｎｒ２ｂｎｍｄａ受容体アンタゴニストとしてのジフルオロエチルピリジン誘導体 |
| AU2015317886A1 (en) | 2014-09-15 | 2017-03-09 | Rugen Holdings (Cayman) Limited | Pyrrolopyrimidine derivatives as NR2B NMDA receptor antagonists |
| WO2016049048A1 (en) | 2014-09-22 | 2016-03-31 | Rugen Holdings (Cayman) Limited | Treatment of anxiety disorders and autism spectrum disorders |
| WO2016100349A2 (en) | 2014-12-16 | 2016-06-23 | Rugen Holdings (Cayman) Limited | Bicyclic azaheterocyclic compounds as nr2b nmda receptor antagonists |
| EP3253761A4 (en) | 2015-02-04 | 2018-06-20 | Rugen Holdings (Cayman) Limited | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists |
| EP3303323B1 (en) | 2015-06-01 | 2020-01-08 | Rugen Holdings (Cayman) Limited | 3,3-difluoropiperidine carbamate heterocyclic compounds as nr2b nmda receptor antagonists |
| EP3544610A1 (en) | 2016-11-22 | 2019-10-02 | Rugen Holdings (Cayman) Limited | Treatment of autism spectrum disorders, obsessive-compulsive disorder and anxiety disorders |
-
2016
- 2016-05-31 EP EP16804257.0A patent/EP3303323B1/en active Active
- 2016-05-31 AU AU2016270677A patent/AU2016270677B2/en active Active
- 2016-05-31 RU RU2017142005A patent/RU2735277C2/ru active
- 2016-05-31 TW TW105117083A patent/TWI721987B/zh active
- 2016-05-31 KR KR1020177037807A patent/KR102613179B1/ko active Active
- 2016-05-31 US US15/578,460 patent/US10584127B2/en active Active
- 2016-05-31 CA CA2987606A patent/CA2987606C/en active Active
- 2016-05-31 CN CN201680042502.8A patent/CN107849010B/zh active Active
- 2016-05-31 WO PCT/US2016/035098 patent/WO2016196513A1/en not_active Ceased
- 2016-05-31 DK DK16804257.0T patent/DK3303323T3/da active
- 2016-05-31 MX MX2017015370A patent/MX380424B/es unknown
- 2016-05-31 AR ARP160101591A patent/AR104837A1/es unknown
- 2016-05-31 ES ES16804257T patent/ES2784398T3/es active Active
- 2016-05-31 JP JP2017562029A patent/JP6876625B2/ja active Active
- 2016-05-31 BR BR112017025023-3A patent/BR112017025023B1/pt active IP Right Grant
-
2017
- 2017-11-24 ZA ZA2017/08006A patent/ZA201708006B/en unknown
- 2017-11-27 IL IL255937A patent/IL255937B/en active IP Right Grant
-
2018
- 2018-08-10 US US16/100,596 patent/US10294230B2/en active Active
-
2020
- 2020-03-05 US US16/810,258 patent/US11136328B2/en active Active
-
2021
- 2021-10-01 US US17/491,676 patent/US20220024937A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272056A (en) | Heterocyclic compounds as adenosine antagonists | |
| IL266472A (en) | Indazole derivatives as alpha-v-integrin antagonists | |
| IL255937B (en) | Heterocyclic compounds 3,3-difluoropiperidine carbamate as nr2b nmda receptor antagonists | |
| IL247854B (en) | Muscarinic receptor antagonists, preparations containing them and their uses | |
| SI3097098T1 (sl) | Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina | |
| IL247194B (en) | Compounds of the cyclopentane type modified in positions 1 and 2 and their use as orexin type receptor antagonists | |
| IL251027A0 (en) | History of pyrrolopyrimidines as nr2b nmda receptor antagonists | |
| IL259617B (en) | Methods for the preparation of 3,1-benzodioxole heterocyclic compounds | |
| SG11202001337XA (en) | Bezimidazole derivatives as adenosine receptor antagonists | |
| SG11202001340VA (en) | Quinoxaline derivatives as adenosine receptor antagonists | |
| ZA201608442B (en) | Methods for the preparation of 1,3-benzodioxole heterocyclic compounds | |
| EP3253761A4 (en) | 3,3-difluoro-piperidine derivatives as nr2b nmda receptor antagonists | |
| SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| HRP20200104T8 (hr) | Novi heterociklični spoj, metoda za pripremu istog, i farmaceutska kompozicija koja sadrži isto | |
| IL258217A (en) | 2,3,4,5 tetrahydropyridin-6-amine derivatives | |
| EP3388423A4 (en) | ANTAGONIST OF THE RECEIVER NK1 | |
| ZA202000758B (en) | Fluoropiperidine compounds as pure 5-ht6 receptor antagonists | |
| ZA201807767B (en) | Angiotensin-1-receptor antagonists | |
| PT3464324T (pt) | Antagonistas de recetores da angiotensina-1 | |
| HK1227385A1 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists |